It is made available under a CC-BY-NC-ND 4.0 International license .

von Willebrand factor-related values can predict bleeding events in patients with left ventricular assist devices

3

4 Ryuichi Taketomi ^{1,2} , MD, Ko Sakatsume ^{1,2} , PhD, Shintaro Katahira ¹ , PhD, Kota Go
--

- 5 Misako Suzuki², MD, Zuo Yunan¹, PhD, Konosuke Sasaki^{1,3}, PhD, Midori Miyatake¹, PhD,
- 6 Katsuhiro Hosoyama¹, PhD, Koki Ito¹, PhD, Yusuke Suzuki¹, PhD, Goro Takahashi¹, PhD,
- 7 Kiichiro Kumagai¹, PhD, Hisanori Horiuchi², PhD, and Yoshikatsu Saiki¹, PhD.
- 8 1. Division of Cardiovascular Surgery, Tohoku University Graduate School of Medicine, Sendai,
- 9 Japan
- 10 2. Department of Molecular and Cellular Biology, Institute of Development, Aging, and Cancer,
- 11 Tohoku University, Sendai, Japan
- 12 3. Oncology Nursing, Health Sciences, Tohoku University Graduate School of Medicine, Sendai,
- 13 Japan
- 14

15 Short title: VWF predicts bleeding in LVAD patients

- 16
- 17 Corresponding authors:
- 18 1. Yoshikatsu Saiki, MD, PhD. Division of Cardiovascular Surgery, Tohoku University Graduate

It is made available under a CC-BY-NC-ND 4.0 International license .

- 19 School of Medicine, 1-1 Seiryomachi, Aoba-ku, Sendai, 980-8574 Japan. Tel: +81-22-7177222; fax:
- 20 +81-22-7177227; e-mail: <u>yoshisaiki@med.tohoku.ac.jp</u>.
- 21 2. Hisanori Horiuchi, MD, PhD. Department of Molecular and Cellular Biology, Institute of
- 22 Development, Aging, and Cancer, Tohoku University, Sendai, Japan, 4-1 Seiryomachi, Aoba-ku,
- 23 Sendai, 980-8575 Japan. Tel: +81-22-7178463; fax: +81-22-7178463; e-mail:
- 24 <u>hisanorihoriuchi@gmail.com</u>
- 25
- 26 Total word count of the manuscript (including Title Page, Abstract, Text, References, Tables and
- 27 Figures Legends) : 5998 words

28

It is made available under a CC-BY-NC-ND 4.0 International license .

29 Abstract

30	Background: Recent advances in left ventricular assist device (LVAD) therapy have significantly
31	contributed to the improved management of severe heart failure. The unignorable risk of bleeding
32	events associated with the device therapy, however, remains to be addressed. Predictive factors for
33	bleeding events are not fully defined.
34	Methods: Patients implanted with various types of LVADs were assessed for von Willebrand factor
35	(VWF)-related values and platelet proteins from 2011 to 2023 at Tohoku University Hospital. We
36	evaluated the relationship between these parameters and bleeding events at remote periods after
37	LVAD implantation.
38	Results: The VWF large multimer index (VWF-LMI), the ratio of VWF ristocetin cofactor activity
39	to VWF antigen level (VWF:RCo/VWF:Ag), and maximal ristocetin (1.2 μ g/mL) induced platelet
40	aggregation (RIPA) rates decreased in a pump speed- and device type-dependent manner. Major
41	bleeding events, defined according to the Interagency Registry for Mechanically Assisted
42	Circulatory Support criteria, occurred in 28.8% (19/66) of the patients. Kaplan-Meier methods,
43	log-rank tests, and Cox regression analyses revealed that VWF-LMI <42.3 (p=0.0002),
44	VWF:RCo/VWF:Ag <0.52 (p=0.0239), and maximal RIPA rate <79.2 (p=0.0012) predicted bleeding
45	events with hazard ratios of 6.96, 2.89, and 13.4, respectively. The platelets of the patients with
46	LVAD support exhibited significantly reduced expression levels of glycoprotein [] (GPVI;

47 1	n=0.0334) at	nd glycoprotei	n □b (GPIb:	p=0.0061) c	compared with	healthy sub	jects. Nevertheless,
11	p=0.055+) u	ind grycoprotein	$\Box \cup (OII0)$	p=0.0001 c	ompared with	nearing sub	jeets. ite vertiferess,

- 48 patients with bleeding events did not exhibit reduced GPVI (p=0.5267) or GPIb (p=0.6674) levels
- 49 compared to those without bleeding events.
- 50 Conclusions: VWF-related values, including VWF-LMI, VWF:RCo/VWF:Ag, and maximal RIPA
- 51 rate, but not reduced platelet proteins, predicted bleeding events in patients with LVADs.
- 52
- 53 **Registration:** URL: <u>https://www.umin.ac.jp/ctr</u>; Unique identifier: UMIN000027761
- 54
- 55 Keywords: left ventricular assist device, bleeding event, von Willebrand factor, platelet protein,
- 56 ristocetin-induced platelet aggregation
- 57

It is made available under a CC-BY-NC-ND 4.0 International license .

58 Clinical Perspective

59 What Is New?

- 60 · Comprehensive measurements of von Willebrand factor-related values, platelet proteins, and
- 61 ristocetin-induced platelet aggregation rates were obtained in patients with left ventricular assist
- 62 device support to evaluate their association with bleeding events.
- 63 The von Willebrand factor large multimer index, ratio of von Willebrand factor ristocetin cofactor
- 64 activity to von Willebrand factor antigen levels, and maximal ristocetin-induced platelet aggregation
- rate predicted bleeding events in patients implanted with a left ventricular assist device.
- 66 What Are the Clinical Implications?
- Predictors of bleeding events in patients with left ventricular assist device support were identified
- in this study. Understanding how von Willebrand factor-related values are associated with bleeding
- 69 events will facilitate the management of potential bleeding events.
- ⁷⁰ The ratio of von Willebrand factor ristocetin cofactor activity to von Willebrand factor antigen
- 71 levels is a predictor of bleeding events that can be measured and evaluated relatively easily in many
- centers without special techniques or equipment, in contrast to analysis of the von Willebrand factor
- 73 large multimer index.

It is made available under a CC-BY-NC-ND 4.0 International license .

74 Introduction

75	Left ventricular assist devices (LVADs) have made tremendous contributions to the
76	treatment of severe heart failure; however, they are associated with complications such as infection,
77	thrombosis, stroke, and bleeding events, which is most commonly gastrointestinal tract bleeding $^{1-3}$.
78	LVAD-associated bleeding is thought to be caused by unphysiologically high shear stress
79	inside the pump, which causes degradation of high-molecular-weight (large) von Willebrand factor
80	(VWF) multimers having a critical role in hemostasis, leading to a hemostatic disorder known as
81	acquired von Willebrand syndrome (AVWS) ^{4,5} . Platelet function is also reportedly impaired in
82	patients with LVADs due to the shedding of glycoprotein \Box (GPVI) and glycoprotein \Box b (GPIb),
83	platelet proteins with important roles in hemostasis ⁶⁻⁹ . Several months after LVAD implantation,
84	fragile and abnormal vessels called angiodysplasia lesions develop in the gastrointestinal tract just
85	underneath the epithelial cells ¹⁰⁻¹² . Thus, gastrointestinal bleeding at remote periods after
86	implantation typically derives from angiodysplasia lesions under impaired hemostatic conditions due
87	to dysfunction of VWFs and/or platelets.
88	Recently developed LVADs with a lower shear stress in the pump seem to be related with
89	fewer LVAD-associated gastrointestinal bleeding events ^{13,14} . Nevertheless, bleeding events remain a
90	common complication in patients with LVADs, accounting for nearly 20.0% of hospital readmissions
91	¹⁵ . Patients with LVADs exhibit a remarkably severe loss of VWF large multimers compared to

92	patients with severe aortic stenosis based on the VWF large multimer index (VWF-LMI), a
93	quantitative score we proposed $5,16-24$ and have widely used $25-27$ to evaluate VWF large multimers in
94	VWF multimer analysis. In the present study, we demonstrated that patients with a bleeding event
95	had significantly lower VWF-LMI values compared to patients without a bleeding event ¹⁸ .
96	The strength of the contribution of VWF impairment and/or platelet dysfunction to
97	bleeding events in patients with LVADs remains unclear. More importantly, no common measures to
98	predict LVAD-associated bleeding events have been developed. To address these issues, we
99	evaluated the association between bleeding events in patients with LVADs and their VWF-related
100	values, including VWF-LMI and platelet protein levels, in patients who underwent LVAD
101	implantation at Tohoku University Hospital.
102	
103	Methods
104	Participants
105	Patients who underwent LVAD implantation at Tohoku University Hospital between July
106	2011 and June 2023, were analyzed. Hematologic analyses were performed when patients were
107	
107	stable. The association between the results of the hematologic analyses and "major bleeding" events
107 108	stable. The association between the results of the hematologic analyses and "major bleeding" events as defined in the IMACS criteria, including suspected internal or external bleeding resulting in death,

It is made available under a CC-BY-NC-ND 4.0 International license .

110 was evaluated.

111	We previously reported an analysis of 41 patients who underwent LVAD implantation and
112	were followed at Tohoku University ¹⁸ . Of those 41 patients, 2 patients were excluded from the
113	analysis as the analyzed blood samples were not obtained under a stable condition (Supplementary
114	figure 1) and 39 patients were analyzed here. Following that report, another 33 patients underwent
115	LVAD implantation at Tohoku University Hospital by June 2023. Excluding 6 patients who declined
116	to participate, transferred to another hospital, or died from postoperative complications, 27 patients
117	were enrolled in the present study. Thus, a total 66 patients with LVADs were analyzed here.
118	Platelet proteins and ristocetin-induced platelet aggregation (RIPA) levels were analyzed
119	in 30 of the 66 patients implanted with LVADs by September 2022, and in 10 enrolled healthy
120	subjects who were not currently taking any medications.
121	
122	Laboratory data
123	Blood samples, collected in sodium citrate at least 1 month after LVAD implantation when
124	patients were stable, were centrifuged at 150 $ imes$ g for 10 min at room temperature to isolate
125	platelet-rich plasma (PRP). Centrifugation at 2,000 \times g for 5 min at room temperature was
126	performed to obtain platelet poor plasma (PPP). Within 2 h after obtaining the PRP and PPP samples,
127	1.2 mg/mL ristocetin was added and RIPA was measured using an automated blood coagulation

128	analyzer (CN6000, Sysmex Corp, Kobe, Japan) according to the manufacturer's instructions. The
129	PRP was also utilized for platelet isolation through gel filtration chromatography ²⁹ . Isolated
130	platelets were suspended in Laemmli's sodium dodecyl sulfate-containing buffer with
131	2-mercaptoethanol and stored at -80°C until use. In parallel, the collected blood samples were
132	centrifuged at 1,200 \times g for 10 min at 4°C to obtain plasma. The obtained plasma was stored at
133	-80°C until use.
134	The VWF ristocetin cofactor activity (VWF:RCo) and VWF antigen levels (VWF:Ag) in
135	the plasma samples from each of the patients were measured with the CN6000 (Sysmex Corp)
136	according to the manufacturer's instructions.
137	
137 138	von Willebrand factor large multimer index
	von Willebrand factor large multimer index VWF-LMI was analyzed using a 1.0% agarose gel to which equal amounts of VWF:Ag
138	
138 139	VWF-LMI was analyzed using a 1.0% agarose gel to which equal amounts of VWF:Ag
138 139 140	VWF-LMI was analyzed using a 1.0% agarose gel to which equal amounts of VWF:Ag were applied under non-reducing conditions followed by Western blotting using FITC-labelled
138 139 140 141	VWF-LMI was analyzed using a 1.0% agarose gel to which equal amounts of VWF:Ag were applied under non-reducing conditions followed by Western blotting using FITC-labelled polyclonal rabbit anti-human VWF antibody (DAKO, Glostrup, Denmark) as the primary antibody.
138 139 140 141 142	VWF-LMI was analyzed using a 1.0% agarose gel to which equal amounts of VWF:Ag were applied under non-reducing conditions followed by Western blotting using FITC-labelled polyclonal rabbit anti-human VWF antibody (DAKO, Glostrup, Denmark) as the primary antibody. The Western blotting analysis probing VWF was visualized by ImmunoStarVR Zeta

It is made available under a CC-BY-NC-ND 4.0 International license .

146 patient's VWF large multimer ratio to that of the control (Siemens Standard plasma) analyzed in the

- 147 lane adjacent to the patient's plasma, as described previously^{5,16-23,25-27}.
- 148

149 Western blotting for platelet proteins evaluation

150	Proteins in the platelet lysate of each patient and control subject, which contained an equal
151	amount of tubulin, were separated by sodium-dodecyl sulphate polyacrylamide-gel electrophoresis
152	using 12.5% e-PAGEL gel (ATTO, Tokyo, Japan). They were then transferred to a nitrocellulose
153	membrane, Protran BA85 (Cytiva), and Western blotting was performed. The primary antibodies
154	used in this study are listed in Supplementary figure 2. Secondary antibodies were mouse
155	anti-human IgG (Jackson ImmunoResearch, West Grove, PA, USA), rabbit anti-human IgG (Jackson
156	ImmunoResearch) or sheep anti-human IgG (R&D Systems, MN, USA). It was finally visualized by
157	ImmunoStar Zeta chemiluminescence (Wako) and quantified using Amersham ImageQuant800
158	(Cytiva) and ImageJ, using the amount of a specific healthy person as 100%.
159	

160 Statistical analyses

All statistical analyses were performed using GraphPad Prism version 10 (GraphPad
Software, San Diego, CA, USA). Continuous variables are expressed as mean ± standard
deviation. Categorical variables are presented as frequencies and percentages, and inter-group

164	comparisons of categorical variables were analyzed using Fisher's exact test or the $\chi 2$ test.
165	Intergroup comparisons of continuous variables were performed using Student's t-test or the Mann
166	Whitney test if normally distributed. Bleeding event-free survivals were analyzed using the
167	Kaplan-Meier method, log-rank test, and Cox regression analysis. Differences were considered
168	significant when the P-value was less than 0.050.
169	
170	Ethics
171	This study was performed in accordance with the Declaration of Helsinki. The study
172	protocol was approved by the Institutional Ethics Committee in Tohoku University (Certification
173	number; 2017-1-386 and 2020-1-935). The study protocol was also registered in the University
174	Hospital Medical Information Network (UMIN) (UMIN number; UMIN000027761). Written
175	informed consent was obtained from each participant.
176	
177	Results
178	Participant characteristics
179	In this study, we analyzed 66 patients with LVADs, as described above (Supplementary
180	figure 1). Age, sex, and blood type did not differ significantly between healthy subjects and patients
181	(Table 1). Patients underwent implantation of various types of LVADs; a centrifugal-type LVAD,

It is made available under a CC-BY-NC-ND 4.0 International license .

including the EVAHEART (Sun Medical Technology Research Corp., Nagano, Japan; n=9),

182

183	HeartMate3 (Abbott, Chicago, IL, USA; n=12), HVAD (Medtronic, Framingham, MA, USA; n=4),
184	DuraHeart (Terumo, Tokyo, Japan; n=4); or an axial-type LVAD, including the Jarvik2000 (Jarvik
185	Heart Inc, New York, NY, USA; n=10) and HeartMate□ (Abbott, Chicago, IL, USA; n=27;Table 1).
186	
187	Evaluation of VWF-LMI
188	VWF multimer analysis of the patients' plasmas was performed by Western blotting under
189	non-reducing conditions (Figure 1A). VWF large multimers were evaluated with the VWF-LMI as
190	described in the Methods. The mean VWF-LMI of the patients was 47.9 \pm 25.4%. We have proposed
191	that VWF-LMI<80.0% reasonably indicates loss of VWF large multimers ²⁴ , and 57 of 66 patients
192	(86.3%) had VWF-LMI<80.0%. Patients with a centrifugal-type LVAD had a higher VWF-LMI than
193	patients with an axial-type LVAD (p<0.001), and patients implanted with an HVAD and DuraHeart
194	had a lower VWF-LMI (Figure 1B). The low VWF-LMIs in patients implanted with an HVAD and
195	DuraHeart having a low pump speed might be due to their outlets with narrow diameters. The
196	VWF-LMI decreased in a pump speed-dependent manner (p<0.001, r=-0.599; Figure 1C).
197	
198	Evaluation of VWF:RCo/VWF:Ag

199 The ratio of VWF:RCo to VWF:Ag can be measured in plasma by an automated blood

It is made available under a CC-BY-NC-ND 4.0 International license .

coagulation analyzer. VWF:RCo/VWF:Ag <0.70 is used for the diagnosis of hereditary von

201	Willebrand disease. The mean VWF:RCo/VWF:Ag for the 66 patients with LVADs was rather low
202	(0.53±0.22), and 51 of 66 patients (77.3%) had VWF:RCo/VWF:Ag <0.70. The VWF-LMI
203	positively correlated with the VWF:RCo/VWF:Ag (p<0.001, r=0.468; Figure 2A). Nevertheless,
204	VWF:RCo/VWF:Ag did not correlate with the device type or pump speed (Figure 2B and C).
205	
206	Evaluation of RIPA
207	Ristocetin is known to induce GPIb platelet protein binding to VWF, which causes platelet
208	aggregation. We analyzed RIPA in 30 patients with LVADs among the enrolled 66 patients as shown
209	in Supplementary figure 1. The mean maximal RIPA rates were 81.4±11.9%, and did not differ
210	significantly from those of healthy subjects, 82.0±8.3% (p=0.834). Nevertheless, VWF-LMI
211	positively correlated with the maximal RIPA rate (p<0.001, r=0.660; Figure 3A). Patients with a
212	centrifugal-type LVAD had a higher maximum RIPA rate compared to patients with an axial-type
213	LVAD (p=0.004) and these values differed significantly between the EVAHEART and Jarvik2000
214	when comparing each device individually (p=0.010; Figure 3B). Maximal RIPA rates decreased in a
215	pump-speed dependent manner (p<0.001, r=-0.664; Figure 3C).
216	

217 Bleeding events

200

It is made available under a CC-BY-NC-ND 4.0 International license .

218	Nineteen patients developed bleeding events among the enrolled 66 patients during the
219	observation period until heart transplantation, death, or bleeding event. Patients developing a
220	bleeding event are summarized in Table 2. Of the 19 patients who developed a bleeding event, 13
221	had gastrointestinal bleeding. Cases 4, 7, 8, and 14 were admitted for evaluation of anemia despite
222	having no bleeding symptoms. All patients were kept on warfarin. Their prothrombin
223	time-international normalized ratios (PT-INRs) were within or below the target range (EVAHEART:
224	2.5-3.5, other devices: 2.0-3.0) except 1 patient whose PT-INR exceeded only slightly the target
225	range at 3.13. Comparison of patients with bleeding events (Bleeding (+)) and those without
226	bleeding events (Bleeding (-)) by univariate analysis revealed significant differences in device type,
227	days on LVAD, VWF-LMI, VWF:RCo/VWF:Ag, lactate dehydrogenase, and platelet counts (Table
228	3). Following multivariate analysis with these factors, however, only VWF-LMI remained
229	statistically significant (p=0.045).
230	
231	Kaplan-Meier curves for bleeding events
232	The receiver operating characteristics (ROC) analysis determined a cutoff value of 42.3%

for VWF-LMI in relation to bleeding events (sensitivity 0.68, specificity 0.84). Using this cutoff value, patients were divided into 2 groups and the Kaplan-Meier curve revealed a significant increase in bleeding events in patients with VWF-LMI <42.3% compared to patients with VWF-LMI

It is made available under a CC-BY-NC-ND 4.0 International license .

236 \geq 42.3% (p<0.001, hazard ratio [HR] 6.96 [95% confidence interval [CI] 2.81-17.2]; Figure 4A).

237The ROC analysis determined a cutoff value of 0.52 for VWF:RCo/VWF:Ag with respect 238 to bleeding events (sensitivity 0.68, specificity 0.68). Using this cutoff value, patients were divided 239 into 2 groups and the Kaplan-Meier curve revealed a significant increase in bleeding events in 240 patients with VWF:RCo/VWF:Ag <0.52 compared to patients with VWF:RCo/VWF:Ag \geq 0.52 241 (p=0.024, HR 2.89 [95%CI 1.17-7.17]; Figure 4B) 242 Six of the 30 patients (20.0%) analyzed for RIPA developed bleeding events. The ROC 243analysis determined a cutoff value of 79.2% for maximal RIPA rate with respect to bleeding events 244 (sensitivity 0.79, specificity 0.83). Using this cutoff value, patients were divided into 2 groups and 245 the Kaplan-Meier curve revealed a significant increase in bleeding events in the patients with a 246 maximal RIPA rate <79.2% compared to patients with a maximal RIPA rate \geq 79.2% (p=0.001, HR 247 13.4 [95%CI 2.22-81.17]; Figure 4C) 248

249 **Evaluation of platelet proteins**

We first confirmed the high specificity of each primary antibody to ensure its adequacy for use in the present study (Figure 5A). With the antibodies, platelets isolated from 30 patients were analyzed by Western blotting by calibrating the PRP volumes based on the amount of tubulin in a control healthy subject. Each result was expressed as a percentage of the control healthy subject's

It is made available under a CC-BY-NC-ND 4.0 International license .

254	expression level. Among 11 platelet proteins, including PAR-1, GPIIIa, P2Y12, and P-selectin, lower
255	expression levels of GPIb (89.3 \pm 6.3 vs 77.4 \pm 18.2, p=0.006) and GPVI (108.8 \pm 9.0 vs 81.3 \pm 33.6,
256	p=0.033) were observed in patients with LVADs (n=30) compared to healthy subjects (n=10).
257	Expression levels of PAR-1 (p=0.210), TXA2R (p=0.221), GPIIIa (p=0.842), FcRy (p=0.678), P2Y1
258	(p=0.072), P2Y12 (p=0.188), 5-HTR2 (p=0.286), PGI2R (p=0.770), and P-selectin (p=0.358) did not
259	differ significantly between patients and controls (Figure 5B). The levels of GPIb or GPVI were not
260	associated with the device type or pump speed. Further, the levels of GPIb and GPVI were not
261	different between Bleeding (+) and Bleeding (-) (p=0.667 and p=0.890, respectively)
262	(Supplementary figure 3).

263

264 Discussion

The findings of the present study demonstrated that 19 (28.8%) of the 66 patients with 265266LVADs developed bleeding events during a mean follow-up of 1386.7±667.0 days after LVAD 267implantation. Patients with bleeding events (n=19) had lower VWF-LMI, VWF:RCo/VWF:Ag, and 268maximal RIPA rate than those without bleeding events. The Kaplan-Meier curve showed that 269 VWF-LMI <42.3% (p<0.001), VWF:RCo/VWF:Ag <0.52 (p=0.024), and maximal RIPA rate 270 <79.2% (p=0.001) predicted bleeding events with HRs of 6.96, 2.89, and 13.42, respectively. Thus, 271 we have first found predictive factors for bleeding events in patients with LVAD that are

It is made available under a CC-BY-NC-ND 4.0 International license .

272 VWF-related values including VWF-LMI, VWF:RCo/VWF:Ag and maximal RIPA rates.

273	VWF:RCo/VWF:Ag <0.70 is used to diagnose von Willebrand disease type 2A 30 and can
274	be measured by an automated hemostatic analyzer in ordinary hospitals. Thus, measuring this ratio is
275	much more feasible than measuring VWF-LMI that requires a special Western blotting technique for
276	analyzing huge VWF multimers of ~20,000,000 daltons, and RIPA that requires freshly collected
277	patient's platelets and a light-transmission platelet aggregometer. Furthermore, we have recently
278	reported that VWF:RCo/VWF:Ag <0.70 predicts a loss of VWF large multimers, defined as
279	VWF-LMI <80.0%, with high specificity, but low sensitivity in patients with severe aortic stenosis
280	(AS) ²⁴ . This is probably due to the relatively low degree of loss of VWF large multimers in AS
281	patients having VWF-LMI of 70.0%-80.0% and many AS patients exhibited VWF:RCo/VWF:Ag
282	around 0.70 ²⁴ . VWF:RCo/VWF:Ag in many AS patients were overlapped with those in healthy
283	subjects. Therefore, use of VWF:RCo/VWF:Ag could be limited for the diagnosis of AVWS in AS
284	patients. In contrast, VWF-LMIs in patients with LVADs in the present study were 20.0%-80.0%
285	(47.9 \pm 25.4%), which were much lower compared to those in patients with severe AS. Accordingly,
286	the positive predictive value of VWF:RCo/VWF:Ag < 0.70 for VWF-LMI $< 80.0\%$ is very high with
287	45/51 (88.2%). Thus, VWF:RCo/VWF:Ag <0.70 could be a useful indicator to monitor the loss of
288	VWF large multimers in patients with LVADs.

289

The VWF:RCo/VWF:Ag correlated with VWF-LMI. The majority (51/66; 77.3%) of

290	patients had a VWF:RCo/VWF:Ag <0.70. Importantly, VWF:RCo/VWF:Ag <0.52 predicted
291	bleeding events (p=0.024) with an HR of 2.89 as described above. Thus, VWF:RCo/VWF:Ag may
292	be a useful predictor in centers where VWF-LMI and RIPA are difficult to measure. Since
293	VWF-LMI, which predicted bleeding events with an HR 6.96, is a better predictor than
294	VWF:RCo/VWF:Ag, VWF-LMI is recommended in centers where it can be measured.
295	Maximal RIPA rates also predicted bleeding events, as did VWF-LMI and
296	VWF:RCo/VWF:Ag. However, the reduction in maximal RIPA rates was smaller, with a mean
297	maximal RIPA rates of 81.4% and a cut-off value of 79.2% for bleeding events in 30 patients with
298	LVAD. This may be due to high ristocetin concentrations used for the purpose of differentiating von
299	Willebrand disease.
299 300	Willebrand disease. We recently demonstrated individual variability in VWF fragility in response to shear
300	We recently demonstrated individual variability in VWF fragility in response to shear
300 301	We recently demonstrated individual variability in VWF fragility in response to shear stress ex vivo ²¹ . In this study, VWF-LMI varied from 40.0%-90.0%, even in patients with the
300 301 302	We recently demonstrated individual variability in VWF fragility in response to shear stress ex vivo ²¹ . In this study, VWF-LMI varied from 40.0%-90.0%, even in patients with the HeartMate3, which is currently the most frequently implanted LVAD in the world and is associated
300 301 302 303	We recently demonstrated individual variability in VWF fragility in response to shear stress ex vivo ²¹ . In this study, VWF-LMI varied from 40.0%-90.0%, even in patients with the HeartMate3, which is currently the most frequently implanted LVAD in the world and is associated with fewer bleeding events, indicating individual differences in VWF vulnerability to shear stress ¹⁴ .
300301302303304	We recently demonstrated individual variability in VWF fragility in response to shear stress ex vivo ²¹ . In this study, VWF-LMI varied from 40.0%-90.0%, even in patients with the HeartMate3, which is currently the most frequently implanted LVAD in the world and is associated with fewer bleeding events, indicating individual differences in VWF vulnerability to shear stress ¹⁴ . It is therefore important to measure VWF-related factors, since even in patients with LVADs

It is made available under a CC-BY-NC-ND 4.0 International license .

308	and GPVI than healthy subjects, and that patients with bleeding events had lower GPIb and GPVI
309	expression levels than those without bleeding events ⁹ . It is unclear why decreased GPIb or GPVI
310	was not associated with bleeding events in our study. We consider following reasons; (1) Mondal et
311	al analyzed patients treated with HeartMateII, Jarvik2000, and HVAD9, which degraded VWF
312	multimers more severely shown in this study. They did not, however, analyze VWF. It is highly
313	likely that the patients with bleeding events in their report had reduced VWF large multimers as well
314	as reduced levels of platelet proteins. (2) Although the definitions of bleedings were based on the
315	INTERMACS criteria in both studies, our study excluded perioperative events due to the greater
316	influence of the surgical technique and unstable hemodynamics in the immediate postoperative
317	period. It is possible that platelet surface protein levels are more strongly associated with
318	perioperative bleeding events than AVWS.
319	In conclusion, we demonstrated that VWF-related values including VWF-LMI,
320	VWF:RCo/VWF:Ag, and maximal RIPA rates, but not expression levels of the platelet proteins
321	GPIb or GPVI, could predict bleeding events in patients with LVADs.
322	
323	Limitations

A limitation of this study is that it was a retrospective single-center study analyzing a relatively small number of patients. Especially for platelet protein levels and RIPA, only 30 cases

It is made available under a CC-BY-NC-ND 4.0 International license .

326	were analyzed.
-----	----------------

327

- 329 VWF-LMI, VWF:RCo/VWF:Ag, and maximal RIPA rates can be predictive factors of
- 330 bleeding events in patients with LVADs.
- 331

332 Sources of Funding

- 333 This research was supported by Japan Agency for Medical Research and Development grant
- 334 22ek0109475h0003 and Japan Society for the Promotion of Science KAKENHI grant 20H03760.
- 335

336 Disclosures

- 337 A part of this study was performed in collaboration with Sysmex Corporation.
- 338
- 339
- 340
- 341
- 342

343

It is made available under a CC-BY-NC-ND 4.0 International license .

344

345

346 References

347	1.	McNamara N,	Narroway	H, Willi	ams M, Brookes	s J, Faraş	g J, Cistulli D, Ban	ion P,
348	Marasco	S, Potapov E, Lo	oforte A. Co	ontempor	ary outcomes of o	continuou	s-flow left ventricular	assist
349	devices-a	a systematic	review.	Ann	Cardiothorac	Surg.	2021;10:186-208.	doi:
350	10.21037	//acs-2021-cfmcs-	-35					
351	2.	Michelis KC, Z	hong L, Pe	ltz M, Pa	andey A, Tang W	HW, Roł	natgi A, Young JB, D	razner

352 MH, Grodin JL. Dynamic Forecasts of Survival for Patients Living With Destination Left

353 Ventricular Assist Devices: Insights From INTERMACS. J Am Heart Assoc. 2020;9:e016203. doi:

354 10.1161/JAHA.119.016203

355 3. Llerena-Velastegui J, Santafe-Abril G, Villacis-Lopez C, Hurtado-Alzate C,

356 Placencia-Silva M, Santander-Aldean M, Trujillo-Delgado M, Freire-Ona X, Santander-Fuentes C,

357 Velasquez-Campos J. Efficacy and Complication Profiles of Left Ventricular Assist Devices in Adult

- 358 Heart Failure Management: A Systematic Review and Meta-analysis. Curr Probl Cardiol.
- 359 2023:102118. doi: 10.1016/j.cpcardiol.2023.102118
- 360 4. Matsumoto M, Kawaguchi S, Ishizashi H, Yagi H, Iida J, Sakaki T, Fujimura Y. Platelets
- treated with ticlopidine are less reactive to unusually large von Willebrand factor multimers than are

It is made available under a CC-BY-NC-ND 4.0 International license .

those treated with aspirin under high shear stress. Pathophysiol Haemost Thromb. 2005;34:35-40.

363 doi: 10.1159/000088546

- 364 5. Horiuchi H, Doman T, Kokame K, Saiki Y, Matsumoto M. Acquired von Willebrand
- 365 Syndrome Associated with Cardiovascular Diseases. J Atheroscler Thromb. 2019;26:303-314. doi:
- 366 10.5551/jat.RV17031
- 367 6. Chen Z, Mondal NK, Ding J, Gao J, Griffith BP, Wu ZJ. Shear-induced platelet receptor
- 368 shedding by non-physiological high shear stress with short exposure time: glycoprotein Ibalpha and
- 369 glycoprotein VI. Thromb Res. 2015;135:692-698. doi: 10.1016/j.thromres.2015.01.030
- 370 7. Chen Z, Zhang J, Li T, Tran D, Griffith BP, Wu ZJ. The impact of shear stress on
- 371 device-induced platelet hemostatic dysfunction relevant to thrombosis and bleeding in mechanically
- 372 assisted circulation. Artif Organs. 2020;44:E201-E213. doi: 10.1111/aor.13609
- 8. Lukito P, Wong A, Jing J, Arthur JF, Marasco SF, Murphy DA, Bergin PJ, Shaw JA,
- 374 Collecutt M, Andrews RK, et al. Mechanical circulatory support is associated with loss of platelet
- 375 receptors glycoprotein Ibalpha and glycoprotein VI. J Thromb Haemost. 2016;14:2253-2260. doi:
- 376 10.1111/jth.13497
- Mondal NK, Chen Z, Trivedi JR, Sorensen EN, Pham SM, Slaughter MS, Griffith BP, Wu
 ZJ. Association of Oxidative Stress and Platelet Receptor Glycoprotein GPIbalpha and GPVI
 Shedding During Nonsurgical Bleeding in Heart Failure Patients With Continuous-Flow Left

medRxiv preprint doi: https://doi.org/10.1101/2023.12.15.23299936; this version posted December 17, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

380 Ventricular Assist Device Support. ASAIO J. 2018;64:462-471. doi:

381 10.1097/MAT.000000000000680

- 382 10. Akiyama M, Sakatsume K, Sasaki K, Kawatsu S, Yoshioka I, Takahashi G, Kumagai K,
- 383 Adachi O, Saiki Y. The incidence, risk factors, and outcomes of gastrointestinal bleeding in patients
- 384 with a left ventricular assist device: a Japanese single-center cohort study. J Artif Organs.
- 385 2020;23:27-35. doi: 10.1007/s10047-019-01138-y
- 386 11. Bartoli CR, Zhang DM, Hennessy-Strahs S, Kang J, Restle DJ, Bermudez C, Atluri P,
- 387 Acker MA. Clinical and In Vitro Evidence That Left Ventricular Assist Device-Induced von
- 388 Willebrand Factor Degradation Alters Angiogenesis. Circ Heart Fail. 2018;11:e004638. doi:

389 10.1161/CIRCHEARTFAILURE.117.004638

- 390 12. Kang J, Hennessy-Strahs S, Kwiatkowski P, Bermudez CA, Acker MA, Atluri P,
- 391 McConnell PI, Bartoli CR. Continuous-Flow LVAD Support Causes a Distinct Form of Intestinal
- 392 Angiodysplasia. Circ Res. 2017;121:963-969. doi: 10.1161/CIRCRESAHA.117.310848

- 394 GA, Tatooles AJ, Silvestry SC, et al. Hemocompatibility-Related Outcomes in the MOMENTUM 3
- 395 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in
- 396 Advanced Heart Failure. Circulation. 2017;135:2003-2012. doi:
- 397 10.1161/CIRCULATIONAHA.117.028303

^{393 13.} Uriel N, Colombo PC, Cleveland JC, Long JW, Salerno C, Goldstein DJ, Patel CB, Ewald

- 398 14. Mehra MR, Goldstein DJ, Cleveland JC, Cowger JA, Hall S, Salerno CT, Naka Y,
- 399 Horstmanshof D, Chuang J, Wang A, et al. Five-Year Outcomes in Patients With Fully Magnetically
- 400 Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial.
- 401 JAMA. 2022;328:1233-1242. doi: 10.1001/jama.2022.16197
- 402 15. Cai J, Xia W, Greenberg P, Okwuosa I, Setoguchi S, Akhabue E. Relation of
- 403 Sociodemographic Factors With Primary Cause of Hospitalization Among Patients With Left
- 404 Ventricular Assist Devices (from the National Inpatient Sample 2012 to 2017). Am J Cardiol.
- 405 2022;180:81-90. doi: 10.1016/j.amjcard.2022.06.047
- 406 16. Tamura T, Horiuchi H, Imai M, Tada T, Shiomi H, Kuroda M, Nishimura S, Takahashi Y,
- 407 Yoshikawa Y, Tsujimura A, et al. Unexpectedly High Prevalence of Acquired von Willebrand
- 408 Syndrome in Patients with Severe Aortic Stenosis as Evaluated with a Novel Large Multimer Index.
- 409 J Atheroscler Thromb. 2015;22:1115-1123. doi: 10.5551/jat.30809
- 410 17. Sakatsume K, Akiyama M, Saito K, Kawamoto S, Horiuchi H, Saiki Y. Intractable
- 411 bleeding tendency due to acquired von Willebrand syndrome after Jarvik 2000 implant. J Artif
- 412 Organs. 2016;19:289-292. doi: 10.1007/s10047-016-0896-7
- 413 18. Sakatsume K, Saito K, Akiyama M, Sasaki K, Kawatsu S, Takahashi G, Adachi O,
- 414 Kawamoto S, Horiuchi H, Saiki Y. Association between the severity of acquired von Willebrand
- 415 syndrome and gastrointestinal bleeding after continuous-flow left ventricular assist device

- 416 implantation. Eur J Cardiothorac Surg. 2018;54:841-846. doi: 10.1093/ejcts/ezy172
- 417 19. Tamura T, Horiuchi H, Obayashi Y, Fuki M, Imanaka M, Kuroda M, Nishimura S, Amano
- 418 M, Sakamoto J, Tamaki Y, et al. Acquired von Willebrand syndrome in patients treated with
- 419 veno-arterial extracorporeal membrane oxygenation. Cardiovasc Interv Ther. 2019;34:358-363. doi:
- 420 10.1007/s12928-019-00568-y
- 421 20. Shiraishi Y, Tachizaki Y, Inoue Y, Hayakawa M, Yamada A, Kayashima M, Matsumoto M,
- 422 Horiuchi H, Yambe T. Hemolysis and von Willebrand factor degradation in mechanical shuttle shear
- 423 flow tester. J Artif Organs. 2021;24:111-119. doi: 10.1007/s10047-020-01219-3
- 424 21. Sakatsume K, Akiyama M, Sakota D, Hijikata W, Horiuchi H, Maruyama O, Saiki Y.
- 425 Individual Variability in von Willebrand Factor Fragility in Response to Shear Stress: A Possible
- 426 Clue for Predicting Bleeding Risk. Asaio j. 2022;68:1128-1134. doi:
- 427 10.1097/mat.000000000001623
- 428 22. Oishi H, Okada Y, Suzuki Y, Hirama T, Ejima Y, Fujimaki SI, Sugawara S, Okubo N,
- 429 Horiuchi H. Impact of intraoperative use of venovenous extracorporeal membrane oxygenation on
- 430 the status of von Willebrand factor large multimers during single lung transplantation. J Thorac Dis.
- 431 2023;15:4262-4272. doi: 10.21037/jtd-23-275
- 432 23. Yashige M, Inoue K, Zen K, Kobayashi R, Nakamura S, Fujimoto T, Takamatsu K, Sugino
- 433 S, Yamano M, Yamano T, et al. Gastrointestinal Angiodysplasia before and after Treatment of Severe

It is made available under a CC-BY-NC-ND 4.0 International license .

434 Aortic Stenosis. N Engl J Med. 2023;389:1530-1532. doi: 10.1056/NEJMc2306027

435	24.	Okubo	N,	Sugawara	S,	Fujiwara	Τ,	Sakatsume	Κ,	Doman	Т,	Yamashita	М,	Goto	Κ,
-----	-----	-------	----	----------	----	----------	----	-----------	----	-------	----	-----------	----	------	----

- 436 Tateishi M, Suzuki M, Shirakawa R, et al. VWF:RCo/VWF:Ag for diagnosis of acquired von
- 437 Willebrand syndrome caused by aortic stenosis. Research and Practice in Thrombosis and
- 438 Haemostasis. 2023. doi: 10.1016/j.rpth.2023.102284
- 439 25. de Jong A, Dirven RJ, Oud JA, Tio D, van Vlijmen BJM, Eikenboom J. Correction of a
- 440 dominant-negative von Willebrand factor multimerization defect by small interfering RNA-mediated
- 441 allele-specific inhibition of mutant von Willebrand factor. J Thromb Haemost. 2018;16:1357-1368.
- 442 doi: 10.1111/jth.14140
- 443 26. Boender J, Atiq F, Cnossen MH, van der Bom JG, Fijnvandraat K, de Meris J, de Maat
- 444 MPM, van Galen KPM, Laros-van Gorkom BAP, Meijer K, et al. Von Willebrand Factor Multimer
- 445 Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von
- 446 Willebrand Disease. Hemasphere. 2021;5:e542. doi: 10.1097/HS9.00000000000542
- 447 27. Nakamura M, Imamura T, Ueno H, Kinugawa K. Impact of the Severity of Acquired von
- 448 Willebrand Syndrome on the Short-Term Prognosis in Patients with Temporary Mechanical
- 449 Circulatory Support. Medicina (Kaunas). 2022;58. doi: 10.3390/medicina58020238
- 450 28. Pienta MJ, Wu X, Cascino TM, Brescia AA, Abou El Ela A, Zhang M, McCullough JS,
- 451 Shore S, Aaronson KD, Thompson MP, et al. Advancing Quality Metrics for Durable Left

It is made available under a CC-BY-NC-ND 4.0 International license .

452 Ventricular Assist Device Implant: Analysis of the Society of Thoracic Surgeons Intermacs Database.

453	Ann Thorac Surg.	2022:113:1544-1551.	doi: 10.1016/	j.athoracsur.2022.01.031

- 454 29. Yaoita N, Shirakawa R, Fukumoto Y, Sugimura K, Miyata S, Miura Y, Nochioka K, Miura
- 455 M, Tatebe S, Aoki T, et al. Platelets are highly activated in patients of chronic thromboembolic
- 456 pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2014;34:2486-2494. doi:
- 457 10.1161/ATVBAHA.114.304404
- 458 30. James PD, Connell NT, Ameer B, Di Paola J, Eikenboom J, Giraud N, Haberichter S,
- 459 Jacobs-Pratt V, Konkle B, McLintock C, et al. ASH ISTH NHF WFH 2021 guidelines on the
- 460 diagnosis of von Willebrand disease. Blood Adv. 2021;5:280-300. doi:
- 461 10.1182/bloodadvances.2020003265
- 462
- 463
- 464

465

- 466
- 467
- 468

469

It is made available under a CC-BY-NC-ND 4.0 International license .

Table 1 Characteristics of participants in this study

	Healthy subjects	Patients with LVADs	p value
	(n=10)	(n=66)	
Age (years)	38.7±12.5	46.1±13.7	0.097
Male	8	54	0.891
Blood type			0.165
А	3	21	
В	2	21	
0	3	23	
AB	2	1	
Device type			
HeartMate3		12	
EVAHEART		9	
HVAD		4	
DuraHeart		4	
HeartMate		27	
Jarvik2000		10	
Etiology			
DCM		41	
dHCM		8	
ICM		7	
Others		10	

It is made available under a CC-BY-NC-ND 4.0 International license .

Days on LVAD	1386.7±667.0	
State		
Ongoing	25	
Transplanted	28	
Explanted	2	
Death	11	

477

478 Data are presented as mean±standard deviation or n (%). Age was compared by Student's t-test and

479 male and blood type by Fisher's exact test. DCM, dilated cardiomyopathy; dHCM, dilated

480 hypertrophic cardiomyopathy; ICM, ischemic cardiomyopathy.

Case	Days on	Sex	Symptoms	Bleeding site	Device type	Antiplatelet agents	Hb	PT-INR	Plt
	LVAD						(g/dL)		$(10^{3}/\mu L)$
1	17	Male	black stool	intestine	Jarvik2000	aspirin 100 mg	6.9	1.79	20.2
2	32	Male	melena	ascending colon	Jarvik2000	aspirin 100 mg	7.7	3.13	11.8
3	142	Male	black stool	intestine	HeartMate	aspirin 100 mg	7.8	2.85	18.4
4	159	Male	no symptoms	unknown	HeartMate	aspirin 100 mg	6.3	2.23	32.4
5	209	Male	black stool	stomach	HeartMate	aspirin 100 mg	7.2	2.00	13.5
6	266	Male	black stool	stomach	Jarvik2000	aspirin 100 mg	7.1	1.90	14.5
7	311	Male	no symptoms	unknown	HeartMate3	aspirin 100 mg	7.2	1.96	23.8
8	609	Male	no symptoms	unknown	HVAD	clopidogrel 75 mg	8.5	1.52	14.6
9	674	Male	black stool	intestine	HeartMate	aspirin 100 mg	8.5	2.35	25.3
10	685	Male	melena	ascending colon	Jarvik2000	aspirin 100 mg + clopidogrel 75	6.6	2.27	19.1
						mg			
11	791	Male	black stool	intestine	HeartMate	aspirin 100 mg	7.7	2.65	23.0
12	833	Male	black stool	ascending colon	Jarvik2000	aspirin 100 mg + clopidogrel 75	12.4	2.84	9.4
						mg			
13	843	Male	melena	ascending colon	Jarvik2000	clopidogrel 75 mg	7.4	2.40	32.2
14	868	Male	no symptoms	unknown	HVAD	aspirin 100 mg	7.1	1.18	19.4
15	1064	Female	excessive	uterus	HeartMate 🗆	aspirin 100 mg	7.3	2.81	20.8
			menstruation						
16	1110	Male	melena	ascending colon	HeartMate	aspirin 100 mg	6.1	2.73	27.1

481 **Table 2 List of patients developing bleeding events**

17	1123	Male	black stool	intestine	HeartMate	aspirin 100 mg	9.1	2.29	20.9
18	1627	Female	excessive	ovary	Jarvik2000	clopidogrel 50 mg	6.5	1.77	14.7
			menstruation						
19	2470	Female	melena	intestine	Jarvik2000	aspirin 100mg	5.4	1.43	13.1

482

483 Bleeding events defined by the Interagency Registry for Mechanically Assisted Circulatory Support criteria including suspected internal or external

484 bleeding, resulting in death, re-operation, hospitalization, and/or transfusion of red blood cells²⁸, excluding perioperative events²⁸. Hb, hemoglobin; LVAD,

485 left ventricular assist device; PT-INR, prothrombin time-international normalized ratio; Plt, platelet count.

486

It is made available under a CC-BY-NC-ND 4.0 International license .

Table 3 Comparison of characteristics and laboratory data between patients with bleeding

events (Bleeding (+)) and patients without bleeding events (Bleeding (-))

	Bleeding (+)	Bleeding (-)	p value
	(n=19)	(n=47)	
Age (years)	49.3±13.6	44.8±13.7	0.282
Male	16	38	0.746
Blood type			0.903
A	5	16	
В	7	14	
0	7	16	
AB	0	1	
Device type			< 0.001
HeartMate3	1	11	
EVAHEART	0	9	
HVAD	2	2	
DuraHeart	0	4	
Heart Mate 🗆	8	19	
Jarvik2000	8	2	
Etiology			0.558
DCM	11	30	
dHCM	4	4	
ICM	2	5	
Others	2	8	
Days on LVAD	1729.9±626.1	1248.0±638.0	0.005
VWF-LMI (%)	29.7±17.8	55.2±24.4	< 0.001
VWF:Ag (%)	94.6±42.2	99.1±51.3	0.921
VWF:RCo (%)	46.4±31.1	57.7±41.9	0.395
VWF:RCo/VWF:Ag	0.47±0.16	0.56±0.23	0.050
LDH (U/L)	416.1±240.5	286.1±149.9	0.011
BUN (mg/dL)	20.4±11.1	17.1±9.5	0.337
Cre (mg/dL)	1.14±0.46	1.01±0.52	0.113

It is made available under a CC-BY-NC-ND 4.0 International license .

Hb (g/dL)	11.1±2.9	11.8±1.7	0.165	
Plt $(10^{3}/\mu L)$	177.8±74.8	229.0±93.3	0.049	
PT-INR	2.22±0.56	2.38±0.55	0.279	
CRP (mg/dL)	0.53±1.34	0.89±1.71	0.120	

Data are presented as mean ± standard deviation. Comparison between patients with bleeding events (Bleeding (+)) and patients without bleeding events (Bleeding (-)) was performed using Fisher's exact test, Student's t-test, or the Mann Whitney test. BUN, blood urea nitrogen; Cre, creatinine; CRP, c-reactive protein; DCM, dilated cardiomyopathy; dHCM, dilated hypertrophic cardiomyopathy; Hb, hemoglobin; ICM, ischemic cardiomyopathy; LDH, lactate dehydrogenase; LVAD, left ventricular assist device; Plt, platelet counts; PT-INR, prothrombin time international normalized ratio; VWF-LMI, von Willebrand factor large multimer index; VWF:Ag, von Willebrand factor ristocetin cofactor activity; ratio of VWF:RCo to VWF:Ag, VWF:RCo/VWF:Ag.

It is made available under a CC-BY-NC-ND 4.0 International license .

Figure legend

Figure 1

(A) Distribution of von Willebrand factor (VWF) large multimers. Bands above the 10th lowest were classified as large multimers. Compared with VWF large multimers in control subjects, VWF large multimers of patients with the HeartMate3 were reduced and those of patients with the Jarvik2000 were even further reduced.

(B) The VWF large multimer index (VWF-LMI) differed significantly between patients implanted with the EVAHEART and HeartMate \Box (p<0.001), EVAHEART and Jarvik2000 (p<0.001), HeartMate3 and HeartMate \Box (p<0.001), and the HeartMate3 and Jarvik2000 (p<0.001).

(C) VWF-LMI decreased in a pump speed-dependent manner (p<0.001, r=-0.599).

Figure 2

(A) The VWF large multimer index (VWF-LMI) positively correlated with the ratio of VWF ristocetin cofactor activity to VWF antigen levels (VWF:RCo/VWF:Ag; p<0.001, r=-0.468).

(B) Association between device type and VWF:RCo/VWF:Ag. No significant difference was detected between device types.

(C) Pump speed did not correlate with VWF:RCo/VWF:Ag (p=0.170, r=-0.171).

It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 3

(A) The VWF large multimer index (VWF-LMI) positively correlated with maximal ristocetin-induced platelet aggregation (RIPA) rate (p<0.001, r=-0.660).

(B) Association between device type and maximal RIPA rate. The association of the maximal RIPA rate differed significantly between the EVAHEART and Jarvik 2000 (p=0.001).

(C) Maximal RIPA rates decreased in a pump speed-dependent manner (p<0.001 r=-0.664).

Figure 4

Comparison between patients in the 2 groups based on cut-off values determined by receiver operating characteristics curve, using Kaplan-Meier method, log-rank test, and Cox regression analysis revealed (A) a significant increase in bleeding events in the patients with a VWF large multimer index (VWF-LMI) <42.3 compared to the patients with VWF-LMI \geq 42.3 (p<0.001, HR 6.96), (B) a significant increase in bleeding events in the patients with a ratio of VWF ristocetin cofactor activity to VWF antigen levels (VWF:RCo/VWF:Ag) <0.52 compared to patients with VWF:RCo/VWF:Ag \geq 0.52 (p=0.024, HR 2.89), and (C) a significant increase in bleeding events in patients with maximal ristocetin-induced platelet aggregation (RIPA) rates <79.2 compared to patients with maximal RIPA rates \geq 79.2 (p=0.001, HR 13.4). VWF-LMI <42.3, VWF:RCo/VWF:Ag <0.52, and maximal RIPA rate <79.2 predicted bleeding events.

It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 5

(A) Western blotting of each primary antibody. Western blotting was performed on 11 platelet proteins involved in platelet aggregation, including PAR-1, TXA2R, GPIb, GP IIIa, GP VI, FcRγ, P2Y1, P2Y12, 5HTR-2, PGI2R and P-selectin.

(B) Comparison of the levels of platelet proteins, including (a) PAR-1, (b) TXA2R, (c) GP \Box b, (d) GP \Box a, (e) GP \Box , (f) FcR γ , (g) P2Y1, (h) P2Y12, (i) 5HTR-2, (j) PGI2R and (k) P-selectin, between healthy subjects and patients with left ventricular assist devices (LVADs). Of the 11 platelet proteins, only GPIb (p=0.006) and GPVI (p=0.033) were significantly reduced in patients with LVADs. No significant differences in PAR-1 (p=0.210), TXA2R (p=0.221), GPIIIa (p=0.842), FcR γ (p=0.678), P2Y1 (p=0.072), P2Y12 (p=0.188), 5HTR-2 (p=0.286), PGI2R (p=0.770), and P-selectin (p=0.358) were detected between healthy subjects and patients with LVADs. Levels of platelet proteins were not associated with bleeding events.